05/03/2026
Nottingham clinical researchers working to find new hope for patients with End Stage Liver Disease
Liver disease rates are rising in the UK, having quadrupled over the last 40 years 📈
For patients with end stage liver disease (decompensated cirrhosis) there are currently no licensed therapies capable of helping the liver recover and thus preventing the disease from progressing further. New innovations are urgently needed 🔬
Now, Nottingham’s NIHR Clinical Research Facility (CRF) is working with Resolution Therapeutics, a biopharmaceutical company developing Regenerative Macrophage Therapies, on an early-stage clinical trial, called the EMERALD study. We’re investigating whether patients’ own immune cells can be re-engineered to treat end stage liver disease, by helping the liver to recover 🧫
In our video, liver expert Dr Nav Palaniyappan, who is leading the EMERALD study in Nottingham, explains more 👇
For further information contact our Research Communciations Team, [email protected]